These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1130 related items for PubMed ID: 19650167

  • 1. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D, Golubicic I, Gavrilovic D, Kezic I, Jelic S.
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX, Chen XB.
    Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
    [Abstract] [Full Text] [Related]

  • 3. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G, Macciò A, Mulas C, Massa E, Madeddu C, Mura L, Contu P, Versace R.
    Oncol Rep; 2002 Apr; 9(3):661-70. PubMed ID: 11956647
    [Abstract] [Full Text] [Related]

  • 4. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P, Ciuleanu TE, Cernea D, Pelau D, Gaal V, Cebotaru C, Guttman T, Todor N, Ghilezan N.
    J BUON; 2007 Apr; 12(1):33-9. PubMed ID: 17436399
    [Abstract] [Full Text] [Related]

  • 5. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumöhl J, Schmerber J, Koumakis G, Florin MC, Zacharias C, Berghmans T, Mommen P, Ninane V, Klastersky J.
    Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA, Crowley JJ, Jacobs EL, Muirhead M, Goodwin JW, Rinehart JJ, Livingston RB.
    Cancer; 1996 Sep 01; 78(5):998-1003. PubMed ID: 8780537
    [Abstract] [Full Text] [Related]

  • 7. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
    Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD.
    Clin Cancer Res; 1999 Apr 01; 5(4):767-74. PubMed ID: 10213211
    [Abstract] [Full Text] [Related]

  • 8. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2008 Sep 01; 61(3):369-77. PubMed ID: 18308419
    [Abstract] [Full Text] [Related]

  • 9. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
    Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, Carlini P, Boni C, Di Sarra S.
    Cancer; 1999 Apr 01; 85(7):1599-605. PubMed ID: 10193952
    [Abstract] [Full Text] [Related]

  • 10. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ, Fernandes AL, Pereira JR, Curtis JR, Santoro IL.
    Lung Cancer; 2006 Aug 01; 53(2):171-6. PubMed ID: 16757059
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R.
    Lung Cancer; 2009 Jun 01; 64(3):319-25. PubMed ID: 19095327
    [Abstract] [Full Text] [Related]

  • 12. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer].
    Wang YM, Guo LJ, Li LS, Li P, Zheng J, Li L.
    Ai Zheng; 2005 Dec 01; 24(12):1514-7. PubMed ID: 16351804
    [Abstract] [Full Text] [Related]

  • 13. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Lorusso V, Gebbia V, Spada M, Guida M, Cassano G, Brunetti C, Germano D, Nettis G, Izzi G, Galetta D, Giampaglia M, Silvestris N, Colucci G.
    Oncol Rep; 2005 Dec 01; 14(6):1547-51. PubMed ID: 16273254
    [Abstract] [Full Text] [Related]

  • 14. [Phase II study of combination chemotherapy with cisplatin, carboplatin and etoposide (CPVP) in unresectable non-small cell lung cancer: analysis of survival time and prognostic factors].
    Sakurai M, Ichiki M, Hayashi I.
    Gan To Kagaku Ryoho; 1997 Feb 01; 24(3):303-8. PubMed ID: 9051132
    [Abstract] [Full Text] [Related]

  • 15. [Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
    Hua XM, Ren XW, Liu FL, Liu Y, Zhang CJ, Li ZJ, Xu L, Liu JY, Liu YG.
    Zhonghua Zhong Liu Za Zhi; 2004 Oct 01; 26(10):621-5. PubMed ID: 15634526
    [Abstract] [Full Text] [Related]

  • 16. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
    Takifuji N, Fukuoka M, Negoro S, Takada M, Kusunoki Y, Matsui K, Masuda N, Ryu S, Sakai N, Kubota K.
    Gan To Kagaku Ryoho; 1990 Mar 01; 17(3 Pt 2):429-34. PubMed ID: 2157364
    [Abstract] [Full Text] [Related]

  • 17. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G.
    Clin Cancer Res; 2008 Mar 01; 14(5):1464-9. PubMed ID: 18316570
    [Abstract] [Full Text] [Related]

  • 18. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A.
    Lung Cancer; 2007 Nov 01; 58(2):238-45. PubMed ID: 17658655
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.